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Abstract
Doxorubicin is a widely used anticancer drug that causes dose-related cardiotoxicity. The exact mechanisms of doxorubicin 
toxicity are still unclear, partly because most in vitro studies have evaluated the effects of short-term high-dose doxorubicin 
treatments. Here, we developed an in vitro model of long-term low-dose administration of doxorubicin utilizing human 
induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Moreover, given that current strategies for prevention 
and management of doxorubicin-induced cardiotoxicity fail to prevent cancer patients developing heart failure, we also 
investigated whether the GATA4-targeted compound 3i-1000 has cardioprotective potential against doxorubicin toxicity 
both in vitro and in vivo. The final doxorubicin concentration used in the chronic toxicity model in vitro was chosen based 
on cell viability data evaluation. Exposure to doxorubicin at the concentrations of 1–3 µM markedly reduced (60%) hiPSC-
CM viability already within 48 h, while a 14-day treatment with 100 nM doxorubicin concentration induced only a modest 
26% reduction in hiPCS-CM viability. Doxorubicin treatment also decreased DNA content in hiPSC-CMs. Interestingly, 
the compound 3i-1000 attenuated doxorubicin-induced increase in pro-B-type natriuretic peptide (proBNP) expression and 
caspase-3/7 activation in hiPSC-CMs. Moreover, treatment with 3i-1000 for 2 weeks (30 mg/kg/day, i.p.) inhibited doxoru-
bicin cardiotoxicity by restoring left ventricular ejection fraction and fractional shortening in chronic in vivo rat model. In 
conclusion, the results demonstrate that long-term exposure of hiPSC-CMs can be utilized as an in vitro model of delayed 
doxorubicin-induced toxicity and provide in vitro and in vivo evidence that targeting GATA4 may be an effective strategy 
to counteract doxorubicin-induced cardiotoxicity.
Keywords Doxorubicin · Cardiotoxicity · Human induced pluripotent stem cell-derived cardiomyocytes · Transcription 
factors · GATA4-targeted compounds · Cardioprotective
Introduction
Cardiotoxicity is a well-recognized devastating adverse 
outcome related to cancer therapy and can lead to long-
term morbidity (Senkus and Jassem 2011). Its prevalence 
is increasing due to improved long-term survival of can-
cer patients. One of the most commonly used groups of 
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anticancer drugs are the anthracyclines (e.g. doxorubicin, 
daunorubicin and idarubicin) which may cause acute cardiac 
damage that can be reversible, but more commonly cause 
late-onset toxicity that leads to heart failure. Anthracycline 
cardiotoxicity is dose-dependent with the heart failure inci-
dence rates ranging from 0.14 to 48% (Conway et al. 2015). 
If baseline cardiotoxicity risk is high, a prophylactic car-
dioprotective treatment with angiotensin-converting enzyme 
inhibitors, angiotensin II receptor blockers, β-blockers and/
or statins should be considered (Corremans et al. 2019; 
Zamorano et al. 2016). Other strategies to prevent left ven-
tricular dysfunction and heart failure induced by anthracy-
clines include reduction in the cumulative dose and use of 
continuous infusions to decrease peak plasma levels, liposo-
mal formulations and less toxic analogues of anthracyclines 
as well as FDA-approved cardioprotective agent dexrazox-
ane (Zamorano et al. 2016). Unfortunately, none of these 
strategies is efficacious enough to prevent a subset of cancer 
patients developing heart failure.
The exact mechanisms of anthracycline-induced cardio-
toxicity are still unclear, but may involve oxidative stress, 
interaction with DNA topoisomerase II beta, calcium dys-
regulation, iron accumulation, mitochondrial damage, struc-
tural changes, and premature senescence as well as activa-
tion of immune system (Maejima et al. 2008; Octavia et al. 
2012; Renu et al. 2018; Rochette et al. 2015; Zhang et al. 
2012). Anthracyclines (Aries et al. 2004; Bien et al. 2007; 
Esaki et al. 2008; Kim et al. 2003; Kobayashi et al. 2006, 
2010; Koka et al. 2010; Riad et al. 2008) along with ischemia 
(Suzuki et al. 2004) have been shown to induce apoptosis 
and downregulation of transcription factor GATA4 in the 
myocardium. Increased apoptosis has also been observed in 
adult cardiomyocytes in GATA4 knock-out mice and in mice 
with reduced GATA4 levels (Bisping et al. 2006; Oka et al. 
2006) as well as in neonatal cardiomyocytes when GATA4 
has been depleted by adenoviral antisense transcripts (Aries 
et al. 2004). In agreement with these findings, GATA4 over-
expression in vivo by intramyocardial delivery of GATA4 
adenoviral vector prevented myocardial infarction-induced 
apoptosis and adverse remodelling in rats (Rysä et al. 2010). 
Accordingly, overexpression of GATA4 in transgenic mice 
(Kobayashi et al. 2006) or by adenovirus-mediated gene 
transfer in vitro in neonatal cardiomyocytes and HL-1 cells 
prevented anthracycline-induced apoptosis (Aries et  al. 
2004; Kim et al. 2003; Kobayashi et al. 2006). The mecha-
nisms of doxorubicin-induced decrease in GATA4 protein 
levels may involve downregulation of GATA4 gene expres-
sion (Park et al. 2011) or caspase-1-dependent depletion of 
GATA4 protein levels (Aries et al. 2014). On the other hand, 
GATA4 is a transcriptional regulator of the anti-apoptotic 
genes Bcl-xL (Aries et al. 2004; Kitta et al. 2003; Park et al. 
2007) and Bcl-2 (Kobayashi et al. 2006) for which GATA4 
binding activity and Ser-105 phosphorylation are required 
(Kobayashi et al. 2006). Overall, these findings demonstrate 
the significance of GATA4 for cell survival signalling.
One reason for the lack of full understanding of the mech-
anisms of doxorubicin cardiotoxicity may be that traditional 
preclinical models are not appropriate or sufficiently clini-
cally relevant (Madonna et al. 2015). The translatability of 
results from in vitro and in vivo models to human is lim-
ited as these models are unable to reproduce the complex 
pathophysiology of human disease. For instance, animal 
models do not generally take into consideration ageing or 
comorbidities that aggravate drug-induced cardiotoxicities 
in clinical situations. Moreover, most in vitro studies have 
evaluated the effects of short-term high-dose doxorubicin 
treatments (Corremans et al. 2019). Additionally, due to 
interspecies differences, in vitro and in vivo animal models 
do not predict accurately the toxic effects on human heart. 
Thus, better experimental models of doxorubicin cardio-
toxicity are needed to more appropriately simulate clinical 
circumstances as well as the actions of potential cardiopro-
tective agents.
The present study had two main aims. First, we aimed to 
establish an in vitro model of long-term low-dose admin-
istration of doxorubicin utilizing human induced pluripo-
tent stem cell-derived cardiomyocytes (hiPSC-CMs). Cell 
viability was studied with the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. High-content 
analysis (HCA) was used to study changes in DNA content, 
transcription factor GATA4 levels, expression of pro-B-type 
natriuretic peptide (proBNP), as well as caspase activation. 
Additionally, to compare different cardiomyocyte types, tox-
icity was studied in both hiPSC-CMs and primary neona-
tal rat ventricular myocytes (NRVMs). Second, as we have 
recently described a novel family of small-molecule com-
pounds that affect the protein–protein interaction of tran-
scription factors GATA4 and NKX2-5 and improve cardiac 
function in experimental models of myocardial infarction 
and hypertension (Ferreira et al. 2017; Kinnunen et al. 2018; 
Välimäki et al. 2017), we aimed to investigate if the lead 
compound 3i-1000 has cardioprotective potential against 
doxorubicin cardiotoxicity in vitro and in vivo.
Materials and methods
Reagents
Cell culture media, supplements and reagents were pur-
chased from Gibco (Thermo Fisher Scientific, Paisley, 
UK). Bovine serum albumin (BSA), insulin–transfer-
rin–sodium selenite media supplement, sodium pyruvate, 
pancreatin, 4′,6-diamidino-2-phenylindole (DAPI), and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) were purchased from Sigma-Aldrich 
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(Steinheim, Germany). Collagenase type 2 was purchased 
from Worthington Biochemical Corporation (Lakewood, 
New Jersey, USA). Growth Factor-Reduced Matrigel® 
was bought from Corning (Bedford, Massachusetts, USA) 
and gelatin from Merck Millipore (Darmstadt, Germany). 
Doxorubicin hydrochloride for in vitro studies as well as 
small-molecule inhibitors Y-27632, CHIR99021, and Wnt-
C59 were acquired from Tocris Bioscience (Bristol, UK). 
Doxorubicin hydrochloride for the in vivo study was from 
Sigma-Aldrich. The small-molecule compound inhibiting 
GATA4 and NKX2-5 interaction (3i-1000; compound 3 in 
Välimäki et al. 2017), N-[4-(diethylamino)phenyl]-5-methyl-
3-phenylisoxazole-4-carboxamide was purchased from Phar-
matory LTD (Oulu, Finland). The purity of the compound 
(minimum > 95%) was determined by HPLC/MS and 1H 
NMR, and the possibility of aggregation of the compound 
was excluded (Välimäki et al. 2017). The primary antibodies 
used in immunofluorescence stainings were monoclonal rab-
bit anti-GATA4 (Cell Signaling Technology #36966), mono-
clonal mouse anti-proBNP (Abcam #ab13115), monoclonal 
mouse anti-α-actinin (Sigma-Aldrich #A7811), and poly-
clonal rabbit anti-cardiac troponin T (Abcam #ab45932). 
The secondary antibodies used were all purchased from 
Life Technologies (Eugene, Oregon, USA): Alexa Fluor 
488 goat anti-mouse lgG (#A11029), Alexa Fluor 488 goat 
anti-rabbit lgG (#A11034), Alexa Fluor 647 goat anti-mouse 
lgG (#A21236), and Alexa Fluor 647 donkey anti-rabbit lgG 
(#A31573). eBioscience™ Brefeldin A Solution (1000X) 
and CellEvent™ Caspase-3/7 Green Detection Reagent were 
from Invitrogen (Carlsbad, California, USA). The primary 
antibodies used in western blotting were polyclonal rabbit 
anti-GATA4 (Santa Cruz Biotechnology #sc-9053), poly-
clonal rabbit anti-phospho-p38 (Cell Signaling Technology 
#9211), polyclonal rabbit anti-p38 (Cell Signaling Technol-
ogy #9212), and monoclonal mouse anti-GAPDH (Merck 
Millipore #MAB374). The secondary HRP-linked antibodies 
anti-rabbit IgG (#7074) and anti-mouse IgG (#7076) were 
purchased from Cell Signaling Techonology. Quantitative 
real-time polymerase chain reaction (RT-PCR) oligos were 
from Sigma-Aldrich.
Cell cultures
Long-term toxicity was studied in hiPSC-CMs. Acute toxic-
ity was studied in both hiPSC-CMs and primary NRVMs. 
Cell cultures were maintained at 37 °C in a humidified 
atmosphere of 5%  CO2. To investigate if the compound 
3i-1000 is cardioprotective against doxorubicin-induced 
toxicity, the cells were exposed simultaneously to both 
doxorubicin and 3i-1000. The selection of doxorubicin con-
centrations was based on plasma concentrations detected in 
patients undergoing treatment (Creasey et al. 1976; Greene 
et  al. 1983; Muller et  al. 1993; Speth et  al. 1987). The 
selection of 3i-1000 concentrations was based on previous 
studies investigating the efficacy and toxicity of the com-
pound in vitro (Karhu et al. 2018; Välimäki et al. 2017). 
For compound exposures doxorubicin, 3i-1000, and equiva-
lent vehicle dilutions were made separately in the growth 
medium. Compound exposures were started by aspirating 
the old growth media and adding first the media containing 
3i-1000 (or equivalent volume concentration of dimethylsul-
foxide; DMSO) to the cells. Cells were incubated at 37 °C 
for 10–15 min after which the medium containing doxoru-
bicin (or equivalent volume concentration of DMSO) was 
also added to the cells. During long-term exposures, the 
media were replaced with fresh growth media (containing 
doxorubicin and/or 3i-1000) every 3–4 days.
Human induced pluripotent stem cell‑derived 
cardiomyocytes
The iPS(IMR90)-4 line (Yu et al. 2007) was purchased from 
WiCell (Madison, Wisconsin, USA). The stem cells were 
cultured in Essential 8™ medium (E8) on six-well plates 
coated with  Matrigel® (1:50). For passaging, the cells were 
dissociated with  Versene® and resuspended in E8 contain-
ing 10 µM ROCK inhibitor Y-27632. The cells were grown 
until 80–95% confluent. Cardiomyocytes were produced 
from hiPSCs using small-molecule induction, as described 
earlier (Burridge et al. 2014; Karhu et al. 2018). Differen-
tiation was started by adding 6 µM CHIR99021 in RPMI 
1640 medium supplemented with B-27 without insulin 
(RB-ins) to the cells (day 0). After 24 h, CHIR99021 was 
removed and replaced with fresh RB-ins (day 1). On day 3, 
the medium was changed to RB-ins containing 2.5 µM Wnt-
C59 for 48 h. From day 5 to 11, the cells were maintained 
in RB-ins. To purify the cardiomyocyte cultures, on day 11 
and 13, the cells were fed with RPMI 1640 without glu-
cose with B-27 supplement. From day 15 onwards, the cells 
were maintained in RPMI 1640 supplemented with B-27 
(RB + ins). Beating hiPSC-CMs were dissociated between 
days 15 and 17 by incubating them in cell dissociation solu-
tion containing 40% enzyme-free cell dissociation buffer, 
40% RPMI 1640 and 20% trypsin–EDTA (final trypsin con-
centration 0.01%) for 7–8 min. Trypsin was inactivated with 
RB + ins supplemented with 10% foetal bovine serum (FBS). 
After centrifugation the cells were suspended in RB + ins 
with 10% FBS containing 10 µM ROCK inhibitor Y-27632 
and seeded at 17,000–20,000 cells/well on gelatin-coated 
96-well plates. In general, differentiation yielded almost 
pure (> 95%) cardiomyocyte cultures indicating high dif-
ferentiation efficiency. In the experiments, only differentia-
tion batches that were > 95% pure cardiomyocyte cultures 
were used. The cells were let to attach for 2 days, after 
which they were maintained in RB + ins (without FBS) for 
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approximately 1 week before treatments. For compound 
exposures, RB + ins (without FBS) was used.
Primary cardiomyocytes
Primary cultures of NRVMs were prepared from 1 to 
3  day-old Wistar rats, as described earlier (Tölli et  al. 
2014). Animals were sacrificed by decapitation. Ven-
tricles were dissected and cut into small pieces, which 
were then enzymatically digested by incubating them for 
1–1.5 h at 37 °C under 600 rpm shaking conditions in a 
solution containing 100 mM NaCl, 10 mM KCl, 1.2 mM 
 KH2PO4, 4.0 mM  MgSO4, 50 mM taurine, 20 mM glucose, 
10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 2 mg/ml collagenase type 2, 2 mg/ml pancrea-
tin, 100 U/ml penicillin, and 100 µg/ml streptomycin. The 
cell suspension was collected and centrifuged for 5 min at 
160 × g. The supernatant and the top layer of the pellet were 
discarded and the isolated cardiac cells were resuspended 
in Dulbecco’s Modified Eagle Medium/Nutrient Mixture 
F-12 (DMEM/F12) supplemented with 10% FBS, 100 U/
ml penicillin, and 100 µg/ml streptomycin. To reduce the 
number of contaminating non-myocytes (25–45% on day 3 
after cell isolation), the cells were pre-plated onto cell cul-
ture flasks and let attach for 45–60 min in cell culture condi-
tions. Unattached cells (enriched cardiomyocytes) were col-
lected with the medium and seeded at 30,000–40,000 cells/
well in gelatin-coated 96-well plates. Next day, the medium 
was changed to complete serum free medium (CSFM; 
DMEM/F-12 supplemented with 2.5 mg/ml BSA, 5 µg/
ml insulin, 5 μg/ml transferrin, 5 ng/ml selenium, 2.8 mM 
sodium pyruvate, 0.1 nM triiodo-l-thyronine (T3), 100 U/
ml penicillin, and 100 µg/ml streptomycin) for 24 h prior 
to compound treatments. For compound exposures, CSFM 
was used.
Cell viability assay
The cells were exposed to doxorubicin and/or 3i-1000 for 
2–21 days and cell viability was quantified with MTT assay 
(Mosmann 1983). MTT was added to the cells at a final con-
centration of 0.5 mg/ml followed by 2 h incubation in cell 
culture conditions. The medium was aspirated and formed 
formazan crystals were solubilized in DMSO. Absorbance 
was measured at 550 nm and absorbance at 650 nm was 
subtracted as background.
Automated fluorescence microscopy 
and high‑content analysis
The cells were exposed to doxorubicin and/or 3i-1000 for 
1–14 days. For proBNP stainings, cells were additionally 
treated with Brefeldin A (1:1000) for 3 h prior to fixation. 
Alternatively, to study caspase activation, the cells were 
incubated with 7 µM caspase-3/7 detection reagent solu-
tion in phosphate-buffered saline (PBS) with 5% FBS for 
60 min at 37 °C prior to fixation. The cells were fixed with 
4% paraformaldehyde (PFA) for 15 min at room temperature 
(rt) and permeabilized with 0.1% Triton X-100 for 10 min. 
Non-specific binding sites were blocked with 4% FBS in 
PBS for 45 min at rt after which the cells were incubated 
with anti-GATA4 (1:400) or anti-proBNP (1:500) antibody. 
Additionally, a primary antibody against α-actinin (1:600) 
or cardiac troponin T (1:800) was used to identify myocytes. 
After a 60-min incubation with primary antibodies at rt, the 
cells were washed 3 × 5 min with PBS followed by a 45-min 
incubation with Alexa Fluor-conjugated secondary antibod-
ies (1:200, with the exception of Alexa Fluor 647 anti-rabbit 
1:250) and DAPI (1 µg/ml) at rt. The plates were imaged 
and analysed with CellInsight CX5 High-Content Screening 
Platform (Thermo Scientific) using a 10 × objective (Olym-
pus UPlanFL N 10x/0.3). For quantification, the cells were 
first identified based on DAPI fluorescence, which defined 
the nuclear area. Non-myocytes were excluded based on 
absence of α-actinin/cardiac troponin T staining. The thresh-
old for α-actinin/cardiac troponin T fluorescence intensity 
was set manually in each experiment to allow optimal exclu-
sion of non-myocytes. The data were collected only from 
α-actinin/cardiac troponin T positive cells. The intensity of 
GATA4 staining was analysed within the nucleus. The inten-
sity of proBNP staining was analysed in the perinuclear area 
defined by a 4-pixel ring around the nucleus. The threshold 
for proBNP positive cells was set manually in each experi-
ment to adjust for minor variation in staining intensity. The 
intensity of fluorescent caspase-3/7 activity reporter was 
quantified within the nucleus. The threshold for caspase 
positive and caspase negative cells was also set manually 
in each experiment.
Doxorubicin‑induced cardiotoxicity in rats
Doxorubicin was administered i.p. to 7 weeks old male 
Sprague Dawley rats with average weight 216 g (range 
189–245 g) at the dose of 1 mg/kg/day for 10 days (Hayward 
and Hydock 2007). Control animals received an equivalent 
volume of saline. Based on previous experiments, and due 
to its rapid metabolism (Kinnunen et al. 2018), the com-
pound 3i-1000 was administered i.p. at the dose of 15 mg/
kg two times a day for 2 weeks from week 7 to week 9. It 
was diluted to DMSO and administered to animals as 1:1 
dilution in corn oil, control animals receiving DMSO with 
corn oil in equivalent volume. Transthoracic echocardiog-
raphy was performed using the Vevo2100 high-frequency 
high-resolution linear array ultrasound system (FujiFilm 
VisualSonics, Toronto, Canada) and MS-250 transducer 
(13–24 MHz, axial resolution 75 μm, lateral resolution 
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165 μm) by a trained sonographer blinded to the treatments, 
as described previously (Jurado Acosta et al. 2017). Rats 
were sedated with isoflurane or anesthetized with ketamine 
(50 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). Using two-
dimensional imaging, a short axis view of the left ventricle 
(LV) at the level of the papillary muscles was obtained and 
a two-dimensionally guided M-mode recording through the 
anterior and posterior walls of the LV were acquired. End-
systolic and end-diastolic LV dimensions (ESD and EDD) 
as well as the thickness of the interventricular septum and 
posterior wall were measured from the M-mode tracings. LV 
fractional shortening (FS) and ejection fraction (EF) were 
calculated from the M-mode LV dimensions using Eqs. 1 
and 2:
An average of three measurements of each variable were 
used. After echocardiographic measurements at 9 weeks, 
the terminally anesthetized animals were decapitated, hearts 
were excised, and the apex of left ventricle was immersed 
in liquid nitrogen and stored at − 70 °C for further analysis.
RNA isolation from LV tissue and RT‑PCR
The LV tissue was grinded in liquid nitrogen to powder, of 
which 1/3 was used for total RNA isolation using guani-
dine thiocyanate–CsCl method (modified from Cathala et al. 
1983). Shortly, tissue powder was homogenised in 3 ml 
lysis buffer containing 4 M guanidium thiocyanate, 0.1 M 
Tris–HCl (pH 7.5), 7% β-mercaptoethanol and 1.0–2.0% 
Na-lauroylsarcosine with Ultra-Turrax®  (IKA®) and cell 
debris was pelleted for 10 min 3000 rpm (1791×g) 4 °C. 
The supernatant containing RNA was stored in − 80 °C for 
further treatment. RNA was isolated by ultracentrifugation 
overnight through a 5.7 M CsCl cushion at 4 °C. The result-
ing pellet was resuspended in lysis buffer and RNA was pre-
cipitated with 3 M sodium acetate (pH 5.2) (1/10 vol) and 
ice cold absolute ethanol (3 × vol) at least for 1 h at − 20 °C. 
The precipitated RNA was pelleted by centrifugation for 
15–20 min 12,000 rpm (13,520×g) at 4 °C and washed 
with 70% ethanol in diethylpyrocarbonate (DEPC)-treated 
water followed by another centrifugation for 5–10 min as 
described above. The washing was repeated and RNA pellet 
was air dried before dissolving in DEPC-H2O. For quantita-
tive RT-PCR analyses, cDNA was synthesised from total 
RNA with a First-Strand cDNA Synthesis Kit (GE Health-
care Life Sciences) following the manufacturer’s protocol. 
RNA was analysed by RT-PCR on an ABI 7300 sequence 
detection system (Applied Biosystems) using TaqMan chem-
istry. The results were quantified using ΔΔCT method and 
(1)FS(% ) = {(LVEDD − LVESD)∕LVEDD} × 100,
(2)EF(% ) = {(LVEDD)3 − (LVESD)3∕LVEDD3} × 100.
normalised to 18S RNA quantified from the same samples. 
The following sequences of the primers and the fluorogenic 
probe were used in assay: atrial natriuretic peptide (ANP, 
forward:GAA AAG CAA ACT GAG GGC TCTG, reverse:CCT 
ACC CCC GAA GCA GCT , probe: TCG CTG GCC CTC GGA 
GCC T) and B-type natriuretic peptide (BNP, forward: TGG 
GCA GAA GAT AGA CCG GA, reverse: ACA ACC TCA GCC 
CGT CAC AG, probe: CGG CGC AGT CAG TCG CTT GG).
Protein extraction from LV tissue and western blot
Two thirds of the ground LV tissue was homogenised in 
4 ml of lysis buffer (20 mM Tris, 10 mM NaCl, 0.1 mM 
EDTA, 0.1 mM EGTA, pH 8.0) containing protease and 
phosphatase inhibitors (1 mM β-glycerophosphate, 1 mM 
 Na3VO4, 10 µg/ml leupeptin, 10 µg/ml pepstatin, 10 µg/
ml aprotinin, 2 mM benzamidine, 1 mM phenylmethylsul-
fonyl fluoride, 50 mM sodium fluoride, 1 mM dithiothrei-
tol). Of the homogenate, 0.8 ml was used for total protein 
extraction and the rest for nuclear protein extraction. Then, 
0.2 ml of lysis buffer (100 mM Tris–HCl, 750 mM NaCl, 
5 mM EDTA, 5 mM EGTA, 5% Triton X-100, 12.5 mM 
sodium pyrophosphate, 5 mM β-glycerophosphate, 5 mM 
 Na3VO4, pH 7.5) was added into the total protein homogen-
ate and vortexed for 30 s. After a 20-min centrifugation at 
12,500 rpm (14,670×g) at 4 °C, the supernatant containing 
total proteins was collected. For nuclear protein extraction, 
the homogenate was divided into two sets, which were later 
combined. The homogenate was kept on ice for 15 min after 
which NP-40 was added at the final concentration of 0.6%. 
Sample was vortexed vigorously for 15 s and centrifuged 
for 30 s at 12,500 rpm (14,670×g) at 4 °C. The pellet was 
suspended into buffer (20 mM Hepes, 0.4 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, pH 8.0) including inhibitors men-
tioned above and the parallel samples were combined. The 
samples were then vortexed vigorously for 45 min at 4 °C. 
After the final centrifugation at 12,500 rpm for 5 min at 
4 °C, the supernatant containing nuclear proteins was col-
lected. The protein concentrations were determined with the 
Bio-Rad Protein Assay. From each animal, 50 µg of total 
protein or 20 µg nuclear protein was resolved on 12% SDS-
PAGE gel and transferred onto nitrocellulose membrane. 
After blocking the nonspecific background in 5% non-fat 
dry milk, the membranes were incubated with 1:1000 dilu-
tion of primary antibodies, except for anti-GAPDH, which 
was used at 1:100,000 dilution, at 4 °C overnight. After 
washing, the membranes were incubated for 1 h with an 
HRP-conjugated anti-rabbit or anti-mouse secondary anti-
body in 1:2000 dilution. The protein amounts were detected 
by enhanced chemiluminescence with ECL Plus reagents 
(RPN2132, Amersham Biosciences) followed by digitaliza-
tion of chemiluminescence with Luminescent Imager Ana-
lyzer LAS-3000 (Fujifilm) and analysing with Quantity One 
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software 4.6.6.Basic (Bio-Rad Laboratories). For a second 
immunoblotting, the membrane was stripped for 30 min at 
60 °C in stripping buffer (0.16 M Tris–HCl, 6.5% SDS and 
2.25% β-mercaptoethanol), blocked and probed with anti-
bodies as described above.
Statistics
In vitro results are expressed as mean from at least three 
independent experiments with error bars representing the 
standard error of the mean (SEM). For statistical analysis, 
non-normalized raw data was used. Statistical analyses were 
performed using IBM SPSS Statistics 24 software. Statistical 
significance was evaluated with randomized block ANOVA 
(experiment and treatment as factors) followed by Tukey’s 
HSD. In vivo results are expressed as mean with error bars 
representing SEM. For the first series of in vivo results, 
Welch’s t test was used to compare groups NaCl and DOX 
at each time point separately. For the second series of in vivo 
results, Levene’s test was used to analyse the equality of 
variances after which independent-samples t test was used 
to compare groups NaCl + V and DOX + V or DOX + V and 
DOX + 3i-1000. Differences at the level of P < 0.05 were 
considered statistically significant.
Ethics
Animal experiments were carried out in accordance with the 
3R principles of the EU directive 2010/63/EU governing the 
care and use of experimental animals, and following local 
laws and regulations [Finnish Act on the Protection of Ani-
mals Used for Scientific or Educational Purposes (497/2013, 
Government Decree on the Protection of Animals Used for 
Scientific or Educational Purposes (564/2013)]. The pro-
tocols were approved by the national Animal Experiment 
Board of Finland (ESAVI-2010-03964/Ym-23).
Results
Doxorubicin‑induced chronic toxicity in hiPSC‑CMs
To study the long-term toxicity in vitro, hiPSC-CMs were 
exposed to doxorubicin for up to 21 days. Exposure to 
doxorubicin at concentrations of 1 µM and 3 µM markedly 
reduced hiPSC-CM viability already within 48 h (approxi-
mately 60%, P  < 0.001; Fig.  1a). Treatment of hiPSC-
CMs with 300 nM doxorubicin was less toxic but resulted 
in severe cytotoxicity within 21 days. On the other hand, 
a 14-day exposure to 100 nM doxorubicin induced only a 
modest 26% (P = 0.201) reduction in hiPSC-CM viability. 
Based on these results, doxorubicin at the concentration of 
100 nM for 14 days was chosen for further HCA experiments 
to explore long-term toxicity. To investigate the effects of the 
small-molecule compound 3i-1000 in hiPSC-CMs, the cells 
were exposed to the compound alone or in combination with 
doxorubicin for 7, 14, and 21 days (Fig. 1b). In the MTT 
assay, 3i-1000 alone at 10 µM concentration reduced hiPSC-
CM viability 34% (P = 0.001), 50% (P  < 0.001) and 65% (P 
< 0.001) after 7, 14 and 21 days of exposure, respectively. 
At the concentration of 3 µM, the decrease was only 16% 
even after 21-day exposure. Moreover, 3i-1000 at 3–10 µM 
concentrations had no effect on doxorubicin-induced reduc-
tions in hiPSC-CM viability.
Effects of doxorubicin and 3i‑1000 on DNA content 
and GATA4 levels in hiPSC‑CMs
DAPI is a fluorescent dye that binds to A-T rich sequences 
of double-stranded DNA, thus the fluorescence depends on 
the amount of the DNA in the cells (Kapuscinski 1995). 
To evaluate the effect of doxorubicin and 3i-1000 on DNA 
content in hiPSC-CMs as well as hiPSC-CM density in cul-
ture, DAPI staining and HCA were utilized. Over long-term 
exposure, both doxorubicin and 3i-1000 decreased hiPSC-
CM density in culture (Fig. 2a). After a 4-day exposure, 
doxorubicin-induced reduction in cell density was 12% 
compared to control, and after a 14-day exposure 49%. 
Additionally, a 14-day exposure to 10 µM 3i-1000 alone 
caused an 80% (P = 0.181) reduction in hiPSC-CM num-
ber compared to control, whereas at the concentration of 
3 µM the decrease was 36%. A 4-day exposure to 100 nM 
doxorubicin decreased the average total intensity of DNA 
staining by 18% (P  < 0.001) compared to control and after 
14-day exposure this reduction was 28% (P = 0.003; Fig. 2b). 
We also measured variation in DNA staining intensity as an 
indication of DNA fragmentation leading to distribution of 
DNA fragments around nuclei (Darzynkiewicz et al. 2010; 
Doan-Xuan et al. 2013). Doxorubicin decreased the intra-
nuclear variability of DNA staining intensity by 31% (P 
< 0.001), 37% (P  < 0.001) and 44% (P = 0.009) after 4, 7 
and 14-day exposures, respectively (Supplementary Fig. S1). 
The compound 3i-1000 had no significant effect on the total 
intensity of DNA staining or the intranuclear variability, 
either alone or in combination with doxorubicin. To eluci-
date the effect of doxorubicin and 3i-1000 on GATA4 levels 
in hiPSC-CMs, average GATA4 staining intensity in nucleus 
was analysed using HCA (Fig. 2c). Neither doxorubicin nor 
3i-1000 had statistically significant effect on nuclear GATA4 
staining even after a 14-day exposure.
Effects of doxorubicin and 3i‑1000 on proBNP 
expression in hiPSC‑CMs
BNP is used for the diagnosis of heart failure and car-
diac dysfunction (de Lemos et al. 2003; Ruskoaho 2003) 
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and its synthesis in cardiomyocytes is induced by cellu-
lar stress such as mechanical stretch (Pikkarainen et al. 
2003), hypoxia (Toth et al. 1994), and metabolic stress 
(Bistola et al. 2008), as well as various paracrine signals 
such as endothelin-1 (Bruneau et al. 1997) and cytokines 
(Ma et al. 2004). To evaluate the effect of doxorubicin 
and 3i-1000 on expression of the BNP precursor proBNP 
in hiPSC-CMs, proBNP staining and HCA were utilized. 
A 4-day exposure to 100 nM doxorubicin induced a 3.1-
fold increase (P < 0.001) in the percentage of cardiomyo-
cytes positive for proBNP compared to control (Fig. 3a, b), 
and this was paralleled by increased average intensity of 
proBNP staining in the perinuclear region (Supplementary 
Fig. S2). When the hiPSC-CMs were exposed simulta-
neously to 100 nM doxorubicin and 10 µM 3i-1000 for 
4 days, the percentage of proBNP + cells decreased 60% 
(P < 0.001). Correspondingly, at the 3 µM concentration 
of 3i-1000, the decrease was 20%. On the other hand, per-
centage of proBNP + cells was similar in doxorubicin and 
doxorubicin plus 3i-1000 treated groups at day 7, as well as 
in doxorubicin and doxorubicin plus 3 µM 3i-1000 groups 
at day 14. However, when the cells were exposed simulta-
neously to doxorubicin (100 nM) and 10 µM 3i-1000 for 
14 days, the percentage of proBNP  cells increased 19.3-
fold compared to a 7.7-fold increase in cells exposed to 
100 nM doxorubicin only (Fig. 3b).
Fig. 1  The effect of long-term doxorubicin (DOX) exposure on the 
viability of human induced pluripotent stem cell-derived cardiomyo-
cytes (hiPSC-CMs). To study cell viability, the cells were exposed 
to DOX for 2–21 days after which the MTT assay was performed. a 
Cell viability after DOX treatment expressed as mean ± SEM (n = 4). 
b Cell viability after co-exposure to DOX and 3i-1000 expressed as 
mean + SEM (n = 4). ***P < 0.001 vs. DMSO; **P < 0.01 vs. DMSO; 
*P < 0.05 vs. DMSO; †††P  < 0.001 vs. control; ††P  < 0.01 vs. control 
(randomized block ANOVA followed by Tukey’s HSD)
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Effects of doxorubicin and 3i‑1000 on caspase 
activation in hiPSC‑CMs
To investigate the effect of doxorubicin and 3i-1000 on 
cell death, caspase activation was analysed using HCA. 
Doxorubicin at 100 nM concentration had no effect on the 
percentage of hiPSC-CMs positive for the fluorescent cas-
pase-3/7 activity reporter after a 4-day exposure, but tended 
to increase after a 7-day exposure and produced a significant 
3.1-fold increase (P = 0.001) in the percentage of cells with 
active caspase-3/7 after a 14-day exposure (Fig. 3d). The 
compound 3i-1000 alone at 10 µM concentration caused a 
5.0-fold increase (P = 0.007) in cells positive for the cas-
pase reporter after a 4-day exposure (Fig. 3c, d). Caspase-3/7 
activity was significantly increased also after 7-day (2.5-
fold, P = 0.007) and 14-day (2.9-fold, P = 0.003) exposures 
Fig. 2  The effects of doxorubicin and 3i-1000 on DNA content and 
GATA4 levels in human induced pluripotent stem cell-derived cardio-
myocytes (hiPSC-CMs) after long-term exposure. For high-content 
analysis, the cells were exposed simultaneously to 100  nM doxo-
rubicin and 3i-1000 for 4, 7 or 14 days after which they were fixed 
and stained. Imaging and analysis was carried out using CellInsight 
High-Content Screening Platform. a Cell density. b Intensity of DNA 
staining. c Intensity of GATA4 staining in nucleus. The results are 
expressed as mean + SEM (n = 3–5). ***P  < 0.001 vs. control; **P 
< 0.01 vs. control (randomized block ANOVA followed by Tukey’s 
HSD)
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to 10 µM 3i-1000. At the 3 µM concentration of 3i-1000, the 
increase was 1.8-fold compared to control at day 14. Interest-
ingly, when the cells were exposed to 10 µM 3i-1000 simul-
taneously with doxorubicin, the increases were only 1.7-fold, 
1.1-fold and 1.9-fold (not statistically significant) compared 
to control at days 4, 7 and 14, respectively, indicating cardio-
myocyte protective effect for 3i-1000 in hiPSC-CMs.
hiPSC‑CMs are more resistant to doxorubicin toxicity 
than primary cardiomyocytes
To compare different cardiomyocyte types, hiPSC-CMs 
and NRVMs were exposed short-term to doxorubicin and 
3i-1000 treatments. Short-term exposures were used because 
NRVMS, unlike hiPSC-CMs, cannot be cultured extended 
periods of time. In the MTT assay, a 48-h exposure to doxo-
rubicin at 1 µM and 3 µM concentrations induced > 58% 
reductions (P  < 0.001) in hiPSC-CM viability (Fig. 4a), 
whereas viability of NRVMs decreased by > 79% (P 
< 0.001; Fig. 4b) (Supplementary Fig. S3 shows  IC50 val-
ues for doxorubicin in both cell types). A 48-h exposure to 
100 nM doxorubicin had no substantial effect on the viability 
of either cardiomyocyte type, while 300 nM doxorubicin 
decreased the viabilities of both cell types by 20%. The com-
pound 3i-1000 (at 10 µM and 30 µM concentrations) alone 
or in the presence of 100 nM doxorubicin tended to increase 
the viabilities of both cell types (approximately 20%).
Based on HCA results (Fig. 5), a 24-h exposure to 100 nM 
doxorubicin induced a 14% decrease (P = 0.039) in the aver-
age intensity of GATA4 staining in NRVM nuclei, but not in 
hiPSC-CMs. Also, 3i-1000 decreased nuclear GATA4 stain-
ing intensity in NRVMs by 15% (P = 0.030). Moreover, a 
24-h exposure to 100 nM doxorubicin had no effect on the 
percentage of cardiomyocytes positive for the fluorescent 
caspase-3/7 activity reporter in either cell type. However, 
a 24-h exposure to 10 µM 3i-1000 by itself induced a 2.5-
fold non-significant increase in hiPSC-CMs and a 1.4-fold 
significant increase (P = 0.037) in NRVMs positive for the 
caspase reporter compared to DMSO, but not in the pres-
ence of 100 nM doxorubicin. It is also notable that in NRVM 
cultures the basal level of caspase + cardiomyocytes after 
24-h exposure to 0.1% DMSO (on day 3 after cell isolation) 
was 8%, whereas in hiPSC-CM cultures the basal level of 
caspase + cells was no more than 1%.
In vivo model of chronic doxorubicin toxicity
As the compound 3i-1000 showed cardioprotective effects 
in hiPSC-CMs in vitro, we next examined its effects on 
doxorubicin-induced cardiotoxicity in  vivo. First, we 
carefully tested several rat and mice models (single 15 or 
20 mg/kg dose of doxorubicin), as described in previous 
GATA4 in vivo cardioprotection studies (Kobayashi et al. 
2006) and in various other studies in which doxorubicin 
has been shown to affect GATA4 levels (Aries et al. 2004; 
Bien et al. 2007; Esaki et al. 2008; Koka et al. 2010; Riad 
et  al. 2008). However, under our experimental condi-
tions, using high bolus dose of 15 mg/kg or 7.5 mg/kg/
week three times i.p. had no effect on LV ejection frac-
tion, instead doxorubicin induced acute diarrhoea and 
ascites, and serious weight loss (18–20%) was observed 
after 7 days in 2/3 of the rats. In our subsequent stud-
ies, we finally observed that the model developed for rats 
by Hayward and Hydock (2007), in which doxorubicin 
was administered at the dose of 1 mg/kg/day for 10 days 
(Fig. 6a), possessed many classical signs of doxorubicin-
induced late-onset dilated cardiomyopathy, reflected as 
the decline in both LV ejection fraction and fractional 
shortening (Fig. 6b, c). Cardiac function was studied by 
echocardiography at 2, 7, 9, and 11 weeks (Fig. 6b, c). The 
cardiomyopathy as consequence of doxorubicin treatment 
started to develop after 7 weeks. At week 9, the LV ejec-
tion fraction in the saline group was 68.8 ± 3.4% (n = 3) 
and DOX group 55.9 ± 3.8% (n = 6) (P = 0.044), and also 
LV fractional shortening was lower in DOX-treated ani-
mals. After week 9, the survival of DOX-treated animals 
decreased quickly (Fig. 6d).
Compound 3i‑1000 restores cardiac function 
in doxorubicin‑treated animals
To study the effect of 3i-1000 on doxorubicin-induced 
cardiotoxicity in  vivo, heart failure was first induced 
with doxorubicin treatment as described in Fig. 6a, and 
the compound 3i-1000 (or equal volume of vehicle) was 
injected i.p. at 30 mg/kg/day (the daily dose was divided 
in two portions) for 2 weeks during the weeks 8 and 9. 
Cardiac function was assessed by echocardiography at 
weeks 2, 7 and 9 (Supplementary Table S1). Interest-
ingly, treatment with compound 3i-1000 significantly 
inhibited doxorubicin-induced cardiotoxicity by restoring 
the left ventricular EF (DOX plus 3i-1000 63.8 ± 2.6% vs. 
DOX 56.8 ± 1.8%, P = 0.041) and FS (DOX plus 3i-1000 
36.4 ± 2.1% vs. DOX 31.2 ± 1.3%, P = 0.043) (Fig. 7a, b). 
There was no changes in left ventricular posterior wall 
thickness (LVPW) or internal dimension (LVID) (Fig. 7c, 
d). Doxorubicin-induced cardiac damage was associated 
with elevation of ANP and BNP mRNA expression and 
these increases in gene expressions were not significantly 
influenced by 3i-1000 treatment (Fig. 7e, f). We did not 
detect any significant changes on GATA4 protein levels 
by western blot analysis, but compound 3i-1000 inhibited 
the doxorubicin-induced decrease in phosphorylated-p38 
protein levels (Supplementary Fig. S4).
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Discussion
Doxorubicin is a widely used chemotherapeutic agent but 
its clinical applications are limited by dose-dependent car-
diotoxicity. Here, we have developed an in vitro model of 
long-term low-dose administration of doxorubicin utilizing 
hiPSC-CMs to more accurately mimic long-term doxoru-
bicin dosing and late effects of cardiotoxicity in clinical 
practice. We exposed hiPSC-CMs to 100 nM doxorubicin for 
up to 21 days, which differs from the other hiPSC-CM-based 
models that have recently been used to study doxorubicin 
toxicity (Burridge et al. 2016; Chaudhari et al. 2016a, b; 
Louisse et al. 2017; Zhao and Zhang 2017). The concentra-
tion of doxorubicin was lower and the exposure time longer, 
which can be expected to more accurately model chronic 
dosing in human cancer patients and the cardiotoxicity that 
ensues. At the same time, it should be taken into account that 
extended exposure times with repeated medium changes may 
cause doxorubicin accumulation in the nuclei and associ-
ated cardiotoxicity (Kawai et al. 1997). The 100 nM concen-
tration was chosen based on cell viability data evaluation. 
Micromolar concentrations of doxorubicin caused severe 
acute toxicity leading to considerable cell death already after 
2 days. This acute toxicity was even more severe in NRVMs 
compared to hiPSC-CMs. Doxorubicin at 100 nM concentra-
tion, however, reduced cell viability over long-term exposure 
without causing excessive cell death. This model also allows 
the evaluation of efficacy of novel cardioprotective or restor-
ative therapies on chronic cardiomyocyte toxicity in vitro.
Doxorubicin can intercalate with DNA, directly affect-
ing transcription and replication, and leading to apoptosis 
of cancer cells (Yang et al. 2014). Doxorubicin-induced 
DNA damage and apoptosis contribute also to its cardio-
toxicity (Arola et al. 2000; Lyu et al. 2007; Rochette et al. 
2015; Zhang et al. 2012). Here we show that doxorubicin-
induced decreases in cell number and viability and DNA 
content were associated with increased caspase-3/7 activity 
in the chronic in vitro cardiotoxicity model, confirming that 
caspase-dependent apoptosis contributed to cardiomyocyte 
death and thus cardiotoxicity. These findings further vali-
date long-term low-dose exposure of hiPSC-CMs as a novel 
model of doxorubicin-induced cardiotoxicity.
To investigate doxorubicin cardiotoxicity in vivo, we 
subjected rats to a once a day regimen of doxorubicin 
for a period of 10 days and then followed up animals for 
11 weeks. In previous studies of doxorubicin-induced car-
diotoxicity, various animal models, doses and dosing regi-
mens have been used (Aston et al. 2017). Here, our aim was 
to study the effect of the compound on cardiac function, and 
therefore, an animal model of doxorubicin-induced cardio-
toxicity, in which the ejection fraction decreases, was nec-
essary. The onset of cardiotoxicity was assessed by means 
of echocardiographic evaluation of cardiac function and 
natriuretic peptide measurements, both recommended also 
in clinical practice as diagnostic tools to detect myocardial 
toxicity (Zamorano et al. 2016). An important character-
istic of the model used herein was the use of low doses of 
doxorubicin that resulted in delayed development of cardiac 
dysfunction, as shown by significant decrease in LV ejection 
fraction and fractional shortening only after week 7. This is 
in contrast to models that administered single or high doses 
of doxorubicin that rapidly damage the heart (Hayward and 
Hydock 2007). The dose of doxorubicin used here, how-
ever, was sufficient to activate left ventricular ANP and BNP 
gene expression, which is consistent with previous reports 
showing their expression to increase in response to cellular 
stress (Kinnunen et al. 1992, 1993; Ogawa et al. 1991; Toth 
et al. 1994). Regarding the clinical value, it is also notewor-
thy to point out that the studies with single high bolus dose 
of doxorubicin have been questioned, since they simulate 
acute cardiotoxicity (Corremans et al. 2019; Gianni et al. 
2008). Therefore, a more relevant experimental design for 
the doxorubicin-induced cardiotoxicity would be the low-
dose and repeated administrations, as this is used in clinics 
(Vejpongsa and Yeh 2014).
Regarding the translational value, it is important to 
compare also the doxorubicin dose used in the present 
experiments to the doses used in humans. In clinical use, 
doxorubicin is administered at the doses of 40–90 mg/
m2 as at least 15 min-long intravenous infusions every 
third week (Vejpongsa and Yeh 2014). For paediatric 
patients and together with other chemotherapeutics lower 
doses are used. When a single dose of 12 mg/kg i.p. was 
administered to mice, doxorubicin plasma concentration 
was 60 ng/ml after 2 h and 20 ng/ml after 24 h (Johansen 
1981). Correspondingly, in humans, 60 mg/m2 dose i.v. 
resulted doxorubicin plasma concentrations 480 ng/ml 
after 1 h and 40 ng/ml after 24 h (Barpe et al. 2010). Thus, 
in the present model in rats, the total cumulative dose of 
10 mg/kg over 10 days roughly resembles a subchronic 
cardiotoxicity model. On the other hand, the cumulative 
Fig. 3  The effects of doxorubicin (DOX) and 3i-1000 on expression 
of pro-B-type natriuretic peptide (proBNP) and caspase activation in 
human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
CMs) after long-term exposure. For high-content analysis, the cells 
were exposed simultaneously to 100 nM DOX and 3i-1000 for 4, 7 or 
14 days after which they were fixed and stained. Imaging and analysis 
was carried out using CellInsight High-Content Screening Platform. a 
Representative images of proBNP staining after a 4-day exposure. b 
Proportion of proBNP positive hiPSC-CMs. c Representative images 
of caspase staining after a 4-day exposure. d Proportion of hiPSC-
CMs positive for fluorescent caspase-3/7 activity reporter. Adjust-
ments of individual colour channels to enhance brightness and con-
trast were made identically to all representative images. The results 
are expressed as mean + SEM (n = 3–4). ***P  < 0.001 vs. control; 
**P  < 0.01 vs. control; *P  < 0.05 vs. control (randomized block 
ANOVA followed by Tukey’s HSD). cTnT cardiac troponin T (colour 
figure online)
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dose 10 mg/kg in rats has been estimated to correspond 
to 400 mg/m2 in humans (80 kg, 183 cm) (Hayward and 
Hydock 2007). Moreover, in vitro concentrations 3 and 
1 µM compare to the initial plasma levels of doxorubicin 
detected in patients after a bolus administration, whereas 
concentrations of 300 and 100 nM compare to the plasma 
levels that are reached within few hours after doxorubicin 
administration and are maintained by continuous infusion 
Fig. 4  The effect of short-term doxorubicin exposure on the viabil-
ity of human induced pluripotent stem cell-derived cardiomyocytes 
(hiPSC-CMs) and neonatal rat ventricular myocytes (NRVMs). 
To study cell viability, a hiPSC-CMs and b NRVMs were exposed 
simultaneously to doxorubicin and 3i-1000 for 48 h after which the 
MTT assay was performed. The results are expressed as mean + SEM 
(n = 3–4). ***P  < 0.001 vs. control; **P  < 0.01 vs. control (rand-
omized block ANOVA followed by Tukey’s HSD)
Fig. 5  The effects of doxorubicin (DOX) and 3i-1000 on GATA4 
levels and caspase activation in human induced pluripotent stem 
cell-derived cardiomyocytes (hiPSC-CMs) and neonatal rat ventricu-
lar myocytes (NRVMs) after short-term exposure. For high-content 
analysis, the cells were exposed simultaneously to 100 nM DOX and 
3i-1000 for 24  h after which they were fixed and stained. Imaging 
and analysis was carried out using CellInsight High-Content Screen-
ing Platform. Representative images of GATA4 staining in a hiPSC-
CMs and b primary NRVM cultures. c Average intensity of nuclear 
GATA4 staining. d Proportion of cardiomyocytes positive for fluores-
cent caspase-3/7 activity reporter. Adjustments of individual colour 
channels to enhance brightness and contrast were made identically to 
all representative images. The results are expressed as mean + SEM 
(n = 3–4). *P  < 0.05 vs. control (randomized block ANOVA followed 
by Tukey’s HSD) (colour figure online)
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(Creasey et al. 1976; Greene et al. 1983; Muller et al. 
1993; Speth et al. 1987).
Using these in vitro and in vivo models, we studied 
whether the GATA4-targeted compound 3i-1000 has car-
dioprotective effects on doxorubicin-induced cardiotoxic-
ity. GATA4 is a member of the GATA family of zinc finger 
transcription factor, which was originally discovered as a 
regulator of cardiac development and subsequently identified 
as a major regulator of cardiac hypertrophy and cell sur-
vival (Pikkarainen et al. 2004; Suzuki 2011; Tremblay et al. 
2018). Several hypertrophic stimuli directly regulate GATA4 
DNA-binding and transcriptional activity in vitro (Hasegawa 
et al. 1997; Majalahti et al. 2007; Morimoto et al. 2000; 
Morisco et al. 2001; Kerkelä et al. 2002) and in vivo (Hau-
tala et al. 2001; Majalahti et al. 2007). Moreover, mechanical 
stretch transiently increases GATA4 DNA-binding activity 
and transcript levels followed by increases in the expression 
of BNP, ANP, and skeletal α-actin genes (Pikkarainen et al. 
2003). Interestingly, GATA4 overexpression alone induces 
hypertrophic myocardial cell growth and hypertrophic gene 
expression in GATA4 transgenic mice (Liang et al. 2001). 
Similarly, overexpression of GATA4 in cell culture by ade-
noviral gene transfer induces cardiomyocyte hypertrophy 
(Liang et al. 2001) and sarcomere reorganization as effi-
ciently as endothelin-1 and phenylephrine (Charron et al. 
2001). For stress-induced cardiac hypertrophic response, the 
GATA4 phosphorylation of Ser-105 has shown to be neces-
sary (van Berlo et al. 2011).
Recently, we have reported the identification of small 
molecules that either inhibit or enhance the GATA4-
NKX2-5 transcriptional synergy (Jumppanen et al. 2019; 
Välimäki et al. 2017). The most potent inhibitor of GATA4-
NKX2-5 interaction, 3i-1000, had no influence on the 
baseline GATA4 proteins levels in NRVMs, whereas the 
phenylephrine-induced elevation in GATA4 Ser-105 phos-
phorylation was significantly inhibited by 3i-1000 (Kin-
nunen et al. 2018). Although the exact mechanisms of action 
remains to established, the compound 3i-1000 inhibits BNP 
transcription, and stretch-, endothelin-1- and phenylephrine-
stimulated gene expression of ANP and BNP, as well as 
hypertrophic cell growth in cardiomyocytes while having 
no effect on GATA4 or NKX2-5 DNA binding or on the 
activity of protein kinases involved in the regulation of 
GATA4 phosphorylation (Välimäki et al. 2017; Kinnunen 
et al. 2018). Moreover, enhanced cardiac function in vivo in 
experimental models of myocardial infarction and hyperten-
sion has been observed (Kinnunen et al. 2018). Importantly, 
in our present experiments, the compound protected from 
doxorubicin-induced cardiac damage, as reflected by the res-
toration of LV ejection fraction and fractional shortening 
in doxorubicin-treated animals. Interestingly, improvement 
in cardiac function by 3i-1000 was not associated with the 
Fig. 6  The in  vivo animal model of doxorubicin (DOX) cardiotox-
icity. The rats received saline or DOX 1 mg/kg/day for 10 days and 
were followed up to 11 weeks. a The experimental design of chronic 
DOX cardiotoxicity in rats. DOX was administered 1  mg/kg/day 
i.p. for 10  days. b, c Cardiac function was measured by echocardi-
ography at 2, 7, 9 and 11 weeks. d The survival of the DOX-treated 
rats decreased quickly after 9  weeks. The results are expressed as 
mean ± SEM; *P  < 0.05 vs. control (Welch’s t test). Number of ani-
mals at 2, 7 and 9  week time points: NaCl = 3; DOX = 6, week 11 
time point: NaCl = 3; DOX = 3. Panels b–d show data from animals 
that were not treated with 3i-1000. ECHO echocardiography
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decrease in left ventricular ANP and BNP mRNA levels, 
suggesting a direct effect of doxorubicin on LV natriuretic 
peptide gene expression.
The compound 3i-1000 showed cardioprotective effects 
also in vitro. It attenuated doxorubicin-induced increase in 
proBNP expression in hiPSC-CMs after a 4-day exposure. 
Moreover, exposure of 3i-1000 at 3 µM and 10 µM concen-
trations attenuated doxorubicin-induced increase in caspase 
activation up to 14 days. The long-term exposures (up to 
21 days), however, revealed toxic effects of 3i-1000 in car-
diomyocytes. In our previous study (Karhu et al. 2018), the 
toxicity of eight compounds (3i-1000 and its derivatives) at 
concentrations ranging from 10 nM to 30 µM on the viabil-
ity of eight different cell types were studied in detail. In 
these short-term experiments (24 h), 3i-1000 was non-toxic 
to cardiomyocytes (NRVMs, hiPSC-CMs), fibroblasts and 
H9c2 cardiac myoblasts. Interestingly, stem cells were very 
sensitive to detect toxicity of 3i-1000 and structure–toxicity 
analysis of all compounds revealed a characteristic dihedral 
angle in the GATA4-targeted compounds that may cause 
stem cell toxicity (Karhu et al. 2018).
Overall, our present in vitro results show that the pro-
tective effects of 3i-1000 on doxorubicin-induced cardio-
toxicity are dependent on dose and treatment time, and 
also suggest distinct mechanisms of action for doxoru-
bicin- and 3i-1000-induced cardiotoxicities. Doxorubicin 
had a direct effect on DNA content in cardiomyocytes, 
leading to caspase activation and apoptosis, whereas com-
pound 3i-1000 had no direct effect on DNA content but 
increased caspase activity. Moreover, the present results 
not only show that 3i-1000 protected cardiomyocytes from 
doxorubicin-induced elevation of proBNP expression but 
Fig. 7  The effect of 3i-1000 on doxorubicin (DOX) cardiotoxicity 
in vivo. The rats received saline or DOX 1 mg/kg/day for 10 days and 
were then treated with compound 3i-1000 30  mg/kg/day or DMSO 
vehicle (V) for 2 weeks (weeks 8 and 9). a–d Left ventricular func-
tional and structural changes measured by echocardiography at the 
end of the experiments. e, f mRNA extracted from left ventricles 
and measured by RT-PCR. The levels of transcripts were normalised 
to ribosomal 18S quantified from the same samples. The results are 
expressed as mean + SEM; *P < 0.05 (independent-samples t test). 
Number of animals: NaCl + V = 10; DOX + V = 9 (except for e, f 
DOX + V = 8); DOX + 3i-1000 = 8. LVPW left ventricular posterior 
wall thickness, LVID left ventricular internal dimension
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also that doxorubicin protected cardiomyocytes from 
3i-1000-induced caspase activation. Cell viability data 
at 7 and 14-day time points show the same effect: expo-
sure to 3i-1000 at 10 µM concentration alone decreased 
hiPSC-CM viability, but this effect was attenuated with 
co-exposure to 100 nM doxorubicin. Thus, it is possible 
that targeting GATA4 with 3i-1000 may be detrimental to 
healthy cardiomyocytes in long-term. On the other hand, 
when cardiomyocytes are exposed to stressors (e.g. doxo-
rubicin), co-treatment with 3i-1000 has protective effects 
in cardiomyocytes. Furthermore, together with our previ-
ous toxicological analysis of 3i-1000 and its derivatives, 
the present data supports further development of 3i-1000 
derivatives.
Interestingly, in the present study doxorubicin had 
no effect on GATA4 protein levels either in vivo or in 
hiPSC-CMs even after long-term exposure. Statistically 
significant changes in GATA4 levels were detected only 
in NRVMs after short-term doxorubicin exposure. In pre-
viously published in vitro studies, in which doxorubicin 
was shown to decrease GATA4 mRNA and protein levels, 
doxorubicin concentrations were higher and exposure times 
shorter, ≤ 24 h (Aries et al. 2004, 2014; Kim et al. 2003; 
Kobayashi et al. 2006, 2010). Similarly, in the prior in vivo 
studies mice were treated with a single high-dose injection 
of doxorubicin (Aries et al. 2004; Kobayashi et al. 2006). 
Therefore, it is possible that the changes in GATA4 levels 
are related to short-term high-dose doxorubicin treatments. 
However, interspecies differences both in vitro and in vivo 
cannot be ruled out. Furthermore, the maturity level of the 
cells and the potential limitations that may entail should 
be considered when utilizing hiPSC-CMs. Although more 
investigations are needed in the future to fully understand 
the exact mechanisms of action of doxorubicin as well as 
the GATA4-targeted compound 3i-1000, our current results 
suggest that their mechanisms of action are not related to 
obvious changes in GATA4 protein levels.
Regarding preclinical drug development, our results high-
light the importance of choosing an appropriate experimen-
tal model for compound testing already in early phases of 
drug discovery projects. The delayed toxicity of GATA4-
targeted compound 3i-1000 demonstrates the significance 
of using longer exposure times in in vitro toxicity screening, 
which is possible when using hiPSC-CMs as these cells can 
be cultured for significantly longer periods of time compared 
to primary cardiomyocytes. Utilizing differentiated human 
cells also eliminates the influence of interspecies differences 
and helps to reduce the use of experimental animals. Fur-
thermore, choosing a suitable model is a key element also 
in investigating the mechanism of doxorubicin cardiotoxic-
ity as reflected by the lack of doxorubicin-induced GATA4 
protein depletion in response to chronic low-dose treatments 
in hiPSC-CMs.
In summary, long-term exposure of hiPSC-CMs is 
a useful in vitro model to investigate the mechanisms of 
delayed doxorubicin-induced cardiotoxicity and novel car-
dioprotective therapies. The GATA4-targeted compound 
3i-1000 exhibited cardioprotective potential in vitro as well 
as in vivo. Over chronic exposure the compound was, how-
ever, toxic to cardiomyocytes and hence further structural 
optimization is required to develop non-toxic derivatives.
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